Clinical trials: SECONDARY PULMONARY HYPERTENSION
Chronic Obstructive Pulmonary Disease, Pulmonary Hypertension
Effects of Ventavis in Patients With Pulmonary Hypertension (PH) Secondary to Chronic Obstructive Pulmonary Disease (COPD)
This is a phase 2, Multi-center, double-blind, randomized, placebo-controlled study to evaluate the effects of inhaled Iloprost in patients with pulmonary hypertension secondary to COPD.
- Trial name
- NCT01437878
- Testing
- Iloprost
- Where
- 11 sites in United States, France and 1 more
- Volunteers
- 2 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension, Idiopathic Pulmonary Fibrosis
Study in Subjects With PAH and PH Secondary to IPF Using Inhaled GeNOsyl.
A Phase 2 open label, dose escalation study to find the minimally and maximum effective dose (dose beyond which no further effect on PVR is seen) of inhaled nitric oxide generated by the GeNOsyl® System compared to placebo.
- Trial name
- PHiano (NCT01265888)
- Testing
- Inhaled Nitric Oxide
- Where
- 10 sites in United States
- Volunteers
- 31 people
- Sponsor
- Geno LLC
Intrahepatic Cholangiocarcinoma (Icc), Advanced Cholangiocarcinoma
Efficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients With Advanced Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/Rearrangements or Mutations
This is an open-label, randomized, controlled, multicenter, phase III clinical study designed to evaluate the efficacy and safety of TT-00420 tablets as monotherapy versus chemotherapy in subjects with unresectable advanced or…
- Trial name
- NCT07328919
- Testing
- TT-00420 (tinengotinib), Oxaliplatin, fluorouracil, calcium folinate, irinotecan, capecitabine
- Where
- 20 sites in China
- Volunteers
- 138 people
- Sponsor
- TransThera Sciences (Nanjing), Inc.
Hypertension Pulmonary Secondary Heart Failure, Right Sided Heart Failure With Normal Ejection Fraction
Open-Label Rollover Study of Levosimendan in PH-HFpEF Patients
PH-HFpEF patients will receive open-label doses of levosimendan and be periodically evaluated for safety in extended use.
- Conditions
- Hypertension Pulmonary Secondary Heart Failure, Right Sided Heart Failure With Normal Ejection Fraction, Heart Failure With Normal Ejection Fraction
- Trial name
- NCT03624010
- Testing
- Levosimendan
- Where
- 9 sites in United States
- Volunteers
- 35 people
- Sponsor
- Tenax Therapeutics, Inc.
Pulmonary Hypertension
Safety and Efficacy Study of Sitaxentan Sodium (Thelin™) in Patients With Pulmonary Arterial Hypertension
The purpose of this study is to evaluate the safety and efficacy of Thelin™ (sitaxsentan sodium) compared to placebo (sugar pill) in the treatment of patients with pulmonary arterial hypertension (PAH).
- Trial name
- NCT00080457
- Testing
- sitaxsentan sodium
- Where
- United States
- Volunteers
- 240 people
- Sponsor
- Encysive Pharmaceuticals
Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)
TX000045-003 is a double-blind, randomized, parallel group, placebo-controlled, proof- of-concept (POC) study, evaluating 2 dose regimens of TX000045 over the course of a 24-week treatment period (the APEX study).
- Trial name
- NCT06616974
- Testing
- TX000045- Dose A, TX000045- Dose B
- Where
- 72 sites in United States, Armenia and 15 more
- Volunteers
- 191 people
- Sponsor
- Tectonic Therapeutic
Hypertension, Pulmonary
Safety Follow-up Study of Inhaled Iloprost in Patients With Pulmonary Hypertension
The aim of this study is to monitor long-term safety and tolerability of iloprost aerosol inhalation therapy in patients suffering from pulmonary hypertension.
- Trial name
- NCT00185315
- Testing
- Ventavis (Iloprost, BAYQ6256)
- Where
- 16 sites in Belgium, France and 5 more
- Volunteers
- 71 people
- Sponsor
- Bayer
Hypertension, Pulmonary
Aerosolized Randomized Iloprost Study II (AIR - II) Long-Term Safety, Tolerability, and Clinical Effects of Iloprost Inhalation in Patients With Primary or Secondary Pulmonary Hypertension
The purpose of this study is to determine whether the study drug is effective in the long-term treatment of primary or secondary pulmonary hypertension
- Trial name
- NCT00414687
- Testing
- Ventavis (Iloprost, BAYQ6256)
- Volunteers
- 63 people
- Sponsor
- Bayer
Anemia, Diabetes, Kidney Disease, Chronic, Hypertension
Study of Anemia in Chronic Kidney Disease (CKD) Among High-Risk Hypertensive and Diabetic Patients in Pakistan
The purpose of this study is to evaluate the prevalence of CKD-related anemia at an early stage through screening of high-risk patients in Pakistan at the level of physicians, cardiologists, and diabetologists.
- Trial name
- NCT02444845
- Where
- 3 sites in Pakistan
- Volunteers
- 246 people
- Sponsor
- Hoffmann-La Roche
Hypertension Pulmonary Secondary, Heart Failure, Right Sided
Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEF
Phase 2 study to evaluate the efficacy and safety of intermittent levosimendan compared with placebo in hemodynamic improvement with exercise in PH-HFpEF subjects
- Conditions
- Hypertension Pulmonary Secondary, Heart Failure, Right Sided, Heart Failure With Normal Ejection Fraction
- Trial name
- HELP (NCT03541603)
- Testing
- Levosimendan
- Where
- 16 sites in United States
- Volunteers
- 44 people
- Sponsor
- Tenax Therapeutics, Inc.